

INITIAL APPLICATION PACKAGE

Non-Confidential

CALL FOR EXPRESSIONS OF INTEREST

GenoTher – Genetic Medicine Acceleration and Incubation Programme

Initial Application Package

July 2026

Application Deadline: September 15, 2026

Submission Guidelines

The purpose of this initial application is to enable the GenoTher Selection Committee to assess:

- The scientific and technological potential of the project;
- The level of innovation;
- The project's stage of development;
- Its medical and industrial potential;

Its alignment with the GenoTher acceleration and incubation programme.

Sensitive information related to intellectual property, detailed scientific data, confidential financial information and industrial strategy will only be requested from shortlisted companies during the confidential Due Diligence phase.

APPLICATION FORMAT

The application package must:

- Not exceed **10 pages** (excluding annexes);
- Be submitted in **English**;
- Be provided in **PDF format**.

Mandatory supporting document:

Company Pitch Deck (10–15 slides) - suggested content at the end of the doc.

Applicants are requested to prepare a document addressing Sections **1 to 12** described below.

1. COMPANY INFORMATION

Company name:

Year of incorporation:

Company status:

-Startup

- Innovative SME

Website:

Country:

Number of employees:

Main business location:

2. CONTACT DETAILS

Primary Contact

Name:

Position:

Email:

Telephone:

Scientific / Technical Contact

Name:

Position:

Email:

3. COMPANY AND TEAM OVERVIEW

Company Overview

Provide a brief description of your company (maximum 10 lines).

Founders and Key Team Members

Please describe:

- Founders' profiles
- Scientific expertise
- Medical expertise
- Industrial expertise
- Entrepreneurial experience

Current Partners

Academic partners:

Industrial partners:

Clinical partners:

Other strategic partners:

4. PROJECT EXECUTIVE SUMMARY

Provide a one-page executive summary addressing:

- What innovation are you developing?
- Which disease(s) are you targeting?
- What unmet medical need does your project address?
- What patient impact do you expect?
- What makes your solution unique?

5. TECHNOLOGY AND INNOVATION

Main Technology Area

- Gene Therapy
- Cell Therapy
- Genome Editing

- Therapeutic RNA
- Delivery Technologies
Biomanufacturing and CMC
- Analytical Technologies
Artificial Intelligence / Digital Biotechnology
- Other

Brief Technology Description

(Maximum one page)

Key Innovation

Please describe:

- The technological breakthrough;
- Your competitive advantage;
- How your approach compares with existing solutions.

6. UNMET MEDICAL NEED AND MARKET OPPORTUNITY

Target indication(s):

Target patient population:

Unmet medical need:

Existing treatment options:

Limitations of current therapies:

Expected value proposition:

7. PROJECT MATURITY

Current Technology Readiness Level (TRL)

TRL 3–4 – Proof of Concept

TRL 5–6 – Preclinical Validation

TRL 7 – Clinical Preparation

TRL 7 – Pre-industrial or Early Clinical Development

Main achievements:

Key milestones reached:

Development objectives for the next 24 months:

8. DEVELOPMENT STRATEGY

Applications from international companies are welcome, provided that part of their development strategy is linked to France, through R&D, industrial, clinical or business activities.

Briefly describe:

Scientific Development

- Key development milestones

Preclinical Development

- Experimental models
- Planned validation studies

Clinical Development

- Overall clinical development strategy

9. INDUSTRIAL STRATEGY AND CMC

Please provide a brief description of:

- Current manufacturing development status:
- Key development needs:
- Major industrial challenges:
- Support required:
- Process Development
- Bioproduction
- GMP Readiness
- Quality Control
- Scale-up

- CDMO Support

10. BUSINESS STRATEGY AND FUNDING

Business Model

- ☐ Proprietary Product
- ☐ Licensing
- ☐ Industrial Partnership
- ☐ Technology Platform
- ☐ Other

Business Development Strategy

- Priority markets:
- Target partnerships:
- Funding
- Capital raised to date:
- Next fundraising milestone:
- Estimated funding requirements:

11. EXPECTATIONS FROM GENOTHER

Why would you like to join the GenoTher acceleration and incubation programme?

(Maximum 10 lines)

What are your three main challenges?

Priority areas where support is expected

- Scientific Expertise
- Regulatory Affairs
- CMC
- Industrialisation
- Intellectual Property
- Business Development
- Fundraising
- Industrial Partnerships

International Expansion

12. SUPPORTING DOCUMENTS

The following documents may be attached:

1. Company Pitch Deck (Mandatory)
2. Scientific Presentation
3. Scientific Publications
4. Executive Business Plan
5. Development Roadmap
- Other Non-Confidential Supporting Documents

DECLARATION

I hereby certify that the information provided in this application is accurate and complete.

Name:

Position:

Date:

Signature:

Recommended Pitch Deck Structure (10–15 Slides)

1. Vision & Mission
2. Unmet Medical Need
3. Proposed Solution
4. Scientific Innovation
5. Technology Platform
6. Development Stage
7. Key Scientific Data
8. Development Strategy
9. CMC & Manufacturing Strategy (High-Level Overview)
10. Regulatory Strategy (High-Level Overview)
11. Market Opportunity

12. Competitive Landscape
13. Business Model
14. Funding Strategy
15. Team
16. Strategic Partners
17. Expectations from GenoTher
18. 24–36 Month Vision